Boron betaine analogs: antitumor activity and effects on Ehrlich ascites tumor cell metabolism

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Biochemistry

Background:

• Boron compounds are explored for therapeutic applications.
• Antitumor activity of novel boron betaine analogs was investigated.
• Understanding mechanisms of action is crucial for drug development.

Purpose of the Study:

• To evaluate the antitumor activity of novel boron betaine analogs.
• To investigate the in vivo and in vitro mechanisms of action of trimethylamine-cyanoborane.
• To establish the feasibility of targeting methyl transfer for cancer therapy.

Main Methods:

• Synthesis and screening of boron betaine analogs against various cancer models (Ehrlich ascites, Walker 256, Lewis lung, B-16 melanoma).
• In vivo studies assessing DNA and protein synthesis, gene modulation, and cyclic-AMP levels.
• In vitro assays to determine the inhibitory effects on key enzymes (DNA polymerase, thymidylate synthetase, methyltransferases, nucleases, cathepsin).

Main Results:

• Boron betaine analogs exhibited antitumor activity in several screens.
• Trimethylamine-cyanoborane inhibited DNA and protein synthesis and modulated gene expression in cancer cells.
• In vitro studies confirmed inhibition of critical enzymes involved in cell proliferation, including those in methyl transfer pathways.
• Increased cyclic-AMP levels were observed with trimethylamine-cyanoborane treatment.

Conclusions:

• Blockage of methyl transfer from S-adenosylmethionine is a viable strategy for controlling cancer cell proliferation.
• While current analogs showed marginal activity, they provide a foundation for developing more potent antitumor agents.
• Further research into boron betaine analogs could lead to novel cancer therapeutics targeting specific biochemical pathways.